177 related articles for article (PubMed ID: 21860862)
1. Structure-activity relationships for organometallic osmium arene phenylazopyridine complexes with potent anticancer activity.
Fu Y; Habtemariam A; Basri AM; Braddick D; Clarkson GJ; Sadler PJ
Dalton Trans; 2011 Oct; 40(40):10553-62. PubMed ID: 21860862
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships for osmium(II) arene phenylazopyridine anticancer complexes functionalised with alkoxy and glycolic substituents.
Needham RJ; Bridgewater HE; Romero-Canelón I; Habtemariam A; Clarkson GJ; Sadler PJ
J Inorg Biochem; 2020 Sep; 210():111154. PubMed ID: 32771772
[TBL] [Abstract][Full Text] [Related]
3. Organometallic osmium arene complexes with potent cancer cell cytotoxicity.
Fu Y; Habtemariam A; Pizarro AM; van Rijt SH; Healey DJ; Cooper PA; Shnyder SD; Clarkson GJ; Sadler PJ
J Med Chem; 2010 Nov; 53(22):8192-6. PubMed ID: 20977192
[TBL] [Abstract][Full Text] [Related]
4. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives.
van Rijt SH; Peacock AF; Johnstone RD; Parsons S; Sadler PJ
Inorg Chem; 2009 Feb; 48(4):1753-62. PubMed ID: 19146436
[TBL] [Abstract][Full Text] [Related]
5. Osmium-arene complexes with high potency towards Mycobacterium tuberculosis.
Coverdale JPC; Guy CS; Bridgewater HE; Needham RJ; Fullam E; Sadler PJ
Metallomics; 2021 Apr; 13(4):. PubMed ID: 33693931
[TBL] [Abstract][Full Text] [Related]
6. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
7. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
Peacock AF; Parsons S; Sadler PJ
J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
[TBL] [Abstract][Full Text] [Related]
8. Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.
Betanzos-Lara S; Novakova O; Deeth RJ; Pizarro AM; Clarkson GJ; Liskova B; Brabec V; Sadler PJ; Habtemariam A
J Biol Inorg Chem; 2012 Oct; 17(7):1033-51. PubMed ID: 22791215
[TBL] [Abstract][Full Text] [Related]
9. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
[TBL] [Abstract][Full Text] [Related]
10. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Selectivity and Localization of Reactive Oxygen Species (ROS) Induction by Osmium Anticancer Complexes That Circumvent Platinum Resistance.
Coverdale JPC; Bridgewater HE; Song JI; Smith NA; Barry NPE; Bagley I; Sadler PJ; Romero-Canelón I
J Med Chem; 2018 Oct; 61(20):9246-9255. PubMed ID: 30230827
[TBL] [Abstract][Full Text] [Related]
12. NMR studies of group 8 metallodrugs:
Needham RJ; Prokes I; Habtemariam A; Romero-Canelón I; Clarkson GJ; Sadler PJ
Dalton Trans; 2021 Sep; 50(37):12970-12981. PubMed ID: 34581369
[TBL] [Abstract][Full Text] [Related]
13. Metal complexes as DNA intercalators.
Liu HK; Sadler PJ
Acc Chem Res; 2011 May; 44(5):349-59. PubMed ID: 21446672
[TBL] [Abstract][Full Text] [Related]
14. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
[TBL] [Abstract][Full Text] [Related]
15. In-Cell Activation of Organo-Osmium(II) Anticancer Complexes.
Needham RJ; Sanchez-Cano C; Zhang X; Romero-Canelón I; Habtemariam A; Cooper MS; Meszaros L; Clarkson GJ; Blower PJ; Sadler PJ
Angew Chem Int Ed Engl; 2017 Jan; 56(4):1017-1020. PubMed ID: 28000997
[TBL] [Abstract][Full Text] [Related]
16. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.
Chen H; Parkinson JA; Parsons S; Coxall RA; Gould RO; Sadler PJ
J Am Chem Soc; 2002 Mar; 124(12):3064-82. PubMed ID: 11902898
[TBL] [Abstract][Full Text] [Related]
17. Functionalization of osmium arene anticancer complexes with (poly)arginine: effect on cellular uptake, internalization, and cytotoxicity.
Rijt SH; Kostrhunova H; Brabec V; Sadler PJ
Bioconjug Chem; 2011 Feb; 22(2):218-26. PubMed ID: 21271713
[TBL] [Abstract][Full Text] [Related]
18. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
[TBL] [Abstract][Full Text] [Related]
19. Photoactivated Osmium Arene Anticancer Complexes.
Xue X; Fu Y; He L; Salassa L; He LF; Hao YY; Koh MJ; Soulié C; Needham RJ; Habtemariam A; Garino C; Lomachenko KA; Su Z; Qian Y; Paterson MJ; Mao ZW; Liu HK; Sadler PJ
Inorg Chem; 2021 Dec; 60(23):17450-17461. PubMed ID: 34503331
[TBL] [Abstract][Full Text] [Related]
20. Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.
Hanif M; Nazarov AA; Hartinger CG; Kandioller W; Jakupec MA; Arion VB; Dyson PJ; Keppler BK
Dalton Trans; 2010 Aug; 39(31):7345-52. PubMed ID: 20601976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
